Clinical Trials
7
Active:0
Completed:2
Trial Phases
4 Phases
Phase 2:1
Phase 3:1
Phase 4:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (50.0%)Not Applicable
1 (16.7%)Phase 2
1 (16.7%)Phase 3
1 (16.7%)Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
Not Applicable
Not yet recruiting
- Conditions
- Acute Myocardial Infarction (AMI)Percutaneous Coronary Intervention (PCI)
- Interventions
- Drug: Shexiang Baoxin Pill
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 9588
- Registration Number
- NCT07153744
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms
Recruiting
- Conditions
- IndigestionDyspepsiaBloatingLoss of AppetiteReflux AcidConstipationUpper Abdominal PainFunctional Dyspepsia
- Interventions
- Drug: Danning Tablet
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 4500
- Registration Number
- NCT06755671
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy
Phase 3
Recruiting
- Conditions
- Cervical Spondylotic Myelopathy
- Interventions
- Drug: Shenqi Sherong PillDrug: Placebo
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 428
- Registration Number
- NCT06377072
- Locations
- 🇨🇳
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
Phase 2
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: 3 ampoules of SHPL-49 InjectionDrug: 6 ampoules of SHPL-49 InjectionDrug: 0.9% Sodium Chloride Injection
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-10-28
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 270
- Registration Number
- NCT06202378
- Locations
- 🇨🇳
Beijing Tiantan Hosptial，Capital Medical University, Beijing, Beijing Municipality, China
🇨🇳Yuebei People's Hospital, Shaoguan, Guangdong, China
🇨🇳Hengshui People's Hospital, Hengshui, Hebei, China
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Phase 4
- Conditions
- Non Obstructive Coronary Artery DiseaseAngina PectorisX Syndrome, AnginaCoronary Heart Disease
- Interventions
- Drug: MUSK pill
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Target Recruit Count
- 264
- Registration Number
- NCT04984954
- Locations
- 🇨🇳
Huashan Hospital Fudan University, ShangHai, Shanghai, China
- Prev
- 1
- 2
- Next
News
No news found